{
    "medicine_id": "a1cd9867a2df12385ce28af68e2af848fc0059d9",
    "platform_id": "DB05494",
    "metadata": {
        "name": "Adult Formula 50 60 61 v v Solution",
        "composition": "60 61 v v Elacytarabine",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in leukemia unspecified and melanoma",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "CP 4055 is a fatty acid derivative of cytarabine an approved cytotoxic cancer drug Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia CP 4055 is designed to overcome this limitation and has shown considerable uptake in solid tumour cells CP 4055 is a patented new chemical entity of the nucleoside analog class with improved biological properties and the potential to treat solid tumours such as non small cell lung cancer malignant melanoma and ovarian cancer",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}